8-K: Krystal Biotech Presents Positive Preclinical Data for KB801 Gene Therapy in Neurotrophic Keratitis at ARVO 2025

Krystal Biotech's KB801 gene therapy shows promise for sustained nerve growth factor expression in wounded murine corneas, offering a potential topical treatment for neurotrophic keratitis.

Summary

• Krystal Biotech presented a poster at the ARVO 2025 Annual Meeting highlighting preclinical data for KB801, a gene therapy for neurotrophic keratitis (NK).
• KB801 is a topical treatment designed to deliver nerve growth factor (NGF) to the cornea.
• Studies in mice with corneal wounds showed that KB801 resulted in higher peak NGF levels and more prolonged NGF exposure compared to recombinant human NGF (rhNGF).
• A single dose of KB801 resulted in higher NGF protein levels compared to six doses of rhNGF, mimicking the clinical dosing regimen of cenegermin-bkbj.
• KB801 demonstrated a favorable safety profile in mice with no signs of ocular necrosis and only mild inflammatory infiltrate after repeat dosing.
• The company believes KB801 is a potentially safe and effective redosable topical ocular therapy for sustained NGF expression in the cornea of NK patients.

Sentiment

Score: 8

Explanation: The document presents positive preclinical data for KB801, suggesting a potential improvement over existing treatments for neurotrophic keratitis. The favorable safety profile and improved pharmacokinetic parameters contribute to a positive outlook.

Positives

• KB801 demonstrates sustained NGF expression in the cornea.
• KB801 shows a potentially improved pharmacokinetic profile compared to rhNGF.
• The therapy exhibits a favorable safety profile in preclinical studies.
• KB801-derived NGF protein has analogous bioactivity to commercially available rhNGF.
• KB801 is a potentially safe and effective redosable topical ocular therapy for sustained NGF expression in the cornea of NK patients.

Risks

• The data presented is preclinical and may not translate to human clinical trials.
• Further studies are needed to confirm the long-term safety and efficacy of KB801.
• Regulatory approval is required before KB801 can be marketed.

Future Outlook

Krystal Biotech is developing KB801 as a topical treatment for neurotrophic keratitis, with the goal of providing a more convenient and effective therapy compared to existing treatments.

Industry Context

Neurotrophic keratitis is a rare degenerative disease with limited treatment options. The current standard of care, cenegermin-bkbj, requires frequent dosing, which can be burdensome for patients. KB801 represents a potential advancement in the treatment of NK by offering a less frequent dosing regimen and sustained NGF expression.

Comparison to Industry Standards

• The current standard of care for NK, cenegermin-bkbj (Oxervate), requires six daily doses for eight weeks due to rapid rhNGF clearance.
• KB801 aims to improve upon this by providing sustained NGF expression with less frequent dosing, potentially leading to better patient compliance and outcomes.
• Preclinical data suggests KB801 achieves higher peak NGF levels and prolonged exposure compared to rhNGF, indicating a potentially superior pharmacokinetic profile.
• Companies like Dompé farmaceutici S.p.A., the maker of Oxervate, are the main competitors in the NK treatment market.

Stakeholder Impact

• Positive results could benefit patients with neurotrophic keratitis by providing a more effective and convenient treatment option.
• Successful development and commercialization of KB801 could increase shareholder value.
• The company's employees may benefit from the company's success.

Key Dates

Keywords

KB801, gene therapy, neurotrophic keratitis, NGF, Krystal Biotech, cornea, ARVO, rhNGF